MedTrace Logo

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

NCT05446298 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-04-13

No results posted yet for this study

Summary

This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

Conditions

Interventions

DRUG

ONC-392

ONC-392 will be given by IV infusion, q3w.

DRUG

Pembrolizumab

Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.

Sponsors & Collaborators

Principal Investigators

  • Bradley Monk, MD · GOG Partners

  • Joyce Barlin, MD · GOG Partners

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-22
Primary Completion
2026-08-30
Completion
2026-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05446298 on ClinicalTrials.gov